



ASX ANNOUNCEMENT

1 April 2019

CardieX Interim Corporate Update – March 2019

CardieX Limited (ASX:CDX, the Company) is pleased to report on various corporate activities for its business and operating subsidiaries for the calendar year as at 31 March 2019 including as follows:

AtCor Medical, Inc

- Significant and material expansion of AtCor's contract to supply technology and services to Bayer's multinational heart failure trial with revenues from that trial increasing by ~50% - combined with further expansion of that trial to cover more than 70 trial sites.
- The roll-out of an API-based OEM strategy targeting patient monitors, ambulatory blood pressure monitoring (BPM), home BPM, and smart wearable partnerships.
- Sales tracking internal plan for 2019.

Blumio, Inc

- Deborah trial in New Jersey progressing and expanded to cover additional care areas for patient enrolment.
- Enhanced radar sensor system has been delivered to the CardieX team in Sydney to continue to progress and support CardieX's development activities under the Joint Development Agreement (JDA) between CDX and Blumio.
- Initial validation trials of Blumio sensor completed comparing data outputs against a radial tonometer (the gold standard in measuring arterial stiffness and blood pressure waveform) – a significant milestone in ongoing development activities.
- The results from the validation trials are being published and presented at the IEEE Body Sensor Networks conference in May. The material significance of this is that products that use a tonometer as the source signal (e.g. CardieX's SphygmoCor®) can also use Blumio's sensor.
- This validation work also enables Blumio to move forward to develop an embedded software and associated reference hardware for the sensor module. This is a critical step toward developing the central blood pressure (CBP) reference design under the JDA.



inHealth, Medical Inc

- Anthem telehealth revenues on plan through March 2019.
- Upward revision of internal forecasts for Anthem revenues for FY19.
- Initiating and implementing sleep health collaboration with a global electronic and medical device company (GEMDC) - currently in final stages of negotiation and contract completion. The GEMDC collaboration involves the parties developing programs and products across GEMDC's line of medical and consumer products with an initial focus on chronic sleep disorders. The development and implementation of these products has been advancing during the LOI period and the Company expects them to be launched shortly after the finalisation of the formal contract (which is nearing completion).
- Launching hypertension pilot trial in Florida using SphygmoCor technology with collaboration from some of the leading research institutes in the USA. This will be the first consumer trial of AtCor technology aimed at showing a combined patient outcome with SphygmoCor and telehealth coaching – further advancing our portfolio of health solutions.
- Preparing for diabetes management pilot trial with Kaiser Permanente.

China Product and Technology Partnerships

- Imminent launch for new CardieX China operating company – sales and technical staff recruitment progressing.
- Successful completion of recent product and partnership roadshow in China by CDX executive team.
- Multiple SphygmoCor OEM partnerships under discussion – with NDAs executed.
- Machine-learning powered hypertension management collaboration with major Chinese AI and machine-learning powerhouse under discussion.
- Piloting inHealth telehealth coaching programs through major Chinese telemedicine company with ~140M patient interactions to date through their platform.

On the progress over the last few months CardieX CEO, Craig Cooper commented:

***“We continue to execute and deliver on our plan of building a world class health technology company grounded in our FDA cleared SphygmoCor® technology. As we look at the global landscape to deploy our products and services the scale of what we are doing becomes more and more significant.*”**



Our key mission remains the same – to improve the lives and lifespan of patients globally through better preventative health solutions. Our SphygmoCor® technology in particular, and the multiple proprietary health data outputs that we can extract using AI and machine learning, have the potential to completely disrupt the diagnostic and treatment protocols for cardiovascular disease and hypertension – the largest global population health problem.

Nowhere are we seeing this opportunity more than in China where we will be expanding our presence over the immediate future with key partnerships and product initiatives that we will be updating the market on shortly.”

For more information please contact:

Chief Executive Officer
Craig Cooper
Ph: +61 429 993 399
ccooper@cardiex.com

Investor Relations
Peter Taylor
Ph: +61 412 036 231
peter@nwrcommunications.com.au

CardieX

CardieX is a global health technology company that develops digital and device based solutions for large-scale population health disorders. The Company's XCEL device is the world leader in measuring "central blood pressure" which is considered essential for the management of hypertension and related cardiovascular disorders. CardieX also has a joint venture partnership with Blumio, Inc in Silicon Valley for the development of a radar-based blood pressure sensor incorporating CardieX technology. In November 2018 CardieX Limited entered into an Agreement to purchase up to 50.5% of inHealth Medical Services, Inc as part of cumulative acquisition agreement.

About inHealth

inHealth Medical Services Inc, is a leading US provider of telehealth services, providing digital, e-commerce and mobile tools for patients to connect online with health coaches as part of a patient care program. inHealth's patient care programs are based on long-term clinical trials that demonstrate superior patient outcomes through the use of telehealth coaching services. inHealth has partnerships with some of the leading healthcare institutions in the USA including Anthem, American Well and Kaiser Permanente.